Literature DB >> 2184006

Managing elevated blood lipid concentrations. Who, when and how?

A M Dart1.   

Abstract

Patients with elevated serum cholesterol concentrations, particularly men, should be treated to lessen their chance of subsequent morbidity from coronary heart disease. Reduction of elevated triglyceride levels is more contentious, but is justified in severely affected individuals. The levels requiring treatment can only be judged by consideration of the overall clinical setting, including patient age and sex, the presence of other risk factors and the particular lipoprotein abnormality. In general, relative youth, male sex, a low level of high density lipoprotein (HDL) cholesterol and a strong family history of coronary heart disease will favour vigorous therapy. The possibility that hyperlipoproteinaemia is secondary to some other metabolic disorder should be considered, particularly in regard to elevated triglyceride levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184006     DOI: 10.2165/00003495-199039030-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  71 in total

Review 1.  The role of dietary polyunsaturated fat in lowering blood cholesterol in man.

Authors:  R L Jackson; O D Taunton; J D Morrisett; A M Gotto
Journal:  Circ Res       Date:  1978-04       Impact factor: 17.367

2.  Laboratory test results as predictors of recurrent coronary artery stenosis following angioplasty.

Authors:  G E Austin; M Lynn; J Hollman
Journal:  Arch Pathol Lab Med       Date:  1987-12       Impact factor: 5.534

3.  Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridaemic patients and normal subjects ingesting fish oil.

Authors:  D R Sullivan; T A Sanders; I M Trayner; G R Thompson
Journal:  Atherosclerosis       Date:  1986-08       Impact factor: 5.162

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

Review 5.  The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs.

Authors:  R P Ames
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

6.  Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

Authors:  M J Martin; S B Hulley; W S Browner; L H Kuller; D Wentworth
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

7.  Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study.

Authors:  E A Nikkilä; P Viikinkoski; M Valle; M H Frick
Journal:  Br Med J (Clin Res Ed)       Date:  1984-07-28

8.  Individual variation in the effects of dietary cholesterol on plasma lipoproteins and cellular cholesterol homeostasis in man. Studies of low density lipoprotein receptor activity and 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in blood mononuclear cells.

Authors:  P Mistry; N E Miller; M Laker; W R Hazzard; B Lewis
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

9.  Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.

Authors:  D R Illingworth
Journal:  Ann Intern Med       Date:  1984-11       Impact factor: 25.391

10.  Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man.

Authors:  S M Grundy; H Y Mok; L Zech; M Berman
Journal:  J Lipid Res       Date:  1981-01       Impact factor: 5.922

View more
  2 in total

Review 1.  Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

Authors:  P Chrisp; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 2.  Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols.

Authors:  M Cziraky
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.